These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 19929705)

  • 1. Newer developments in the treatment of Gram-positive infections.
    Koomanachai P; Crandon JL; Nicolau DP
    Expert Opin Pharmacother; 2009 Dec; 10(17):2829-43. PubMed ID: 19929705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gram-positive bacterial infections resistant to antibiotic treatment].
    Utili R
    Ann Ital Med Int; 2001; 16(4):205-19. PubMed ID: 11799629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing antimicrobial therapy for gram-positive bloodstream infections in patients on hemodialysis.
    Pai AB; Pai MP
    Adv Chronic Kidney Dis; 2006 Jul; 13(3):259-70. PubMed ID: 16815231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infections caused by Gram-positive bacteria: a review of the global challenge.
    Woodford N; Livermore DM
    J Infect; 2009 Sep; 59 Suppl 1():S4-16. PubMed ID: 19766888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of linezolid versus comparator therapies in Gram-positive infections.
    Wilcox MH
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii27-35. PubMed ID: 12730140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging serious Gram-positive infections.
    Menichetti F
    Clin Microbiol Infect; 2005 May; 11 Suppl 3():22-8. PubMed ID: 15811021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the antimicrobial resistance patterns of gram-positive cocci isolated from community-private and university-affiliated hospitals from Puerto Rico.
    Vázquez GJ; Robledo IE; Arroyo A; Nadal E; Rodríguez R; Bermudez M; Colón M
    P R Health Sci J; 2003 Jun; 22(2):131-6. PubMed ID: 12866136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
    Carpenter CF; Chambers HF
    Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
    Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of antibiotic-resistant Gram-positive pathogens.
    Lode HM
    Clin Microbiol Infect; 2009 Mar; 15(3):212-7. PubMed ID: 19335368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections].
    Li JT; Li Y; Wang J;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):365-74. PubMed ID: 12820911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
    Leonard SN; Rybak MJ
    Pharmacotherapy; 2008 Apr; 28(4):458-68. PubMed ID: 18363530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of isolation of common gram positive bacterial pathogens and their susceptibilities to antimicrobial agents in Jimma Hospital.
    Gebreselassie S
    Ethiop Med J; 2002 Apr; 40(2):115-27. PubMed ID: 12240573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G; Rossolini GM
    Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Denys GA; Koch KM; Dowzicky MJ
    Am J Infect Control; 2007 Oct; 35(8):521-6. PubMed ID: 17936143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of linezolid in children: an overview of recent advances.
    Velissariou IM
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):947-52. PubMed ID: 17181410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.